NHS Greater Glasgow and Clyde: New Medicines Decisions

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHSScotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and prefere

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultatior medicines for healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines in are consistent across the health board.

How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
    - how well the medicine works,
    - which patients might benefit from it ,
    - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
    - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health a Appraisals (NICE MTAs) are applicable in Scotland.

What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

Why is a particular medicine not routinely available in NHSGGC?

- This is usually because the medicine is not recommended for use in NHSScotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.
- There may also be differences in which medicines are preferred in health boards. Sometimes SMC accepts more than one medicine for treating a specific medical condition. Clinical experts in each medicines to their formulary and advise the ADTC. Sometimes it is agreed that established medicines are a better choice than new medicines.

Medicine	Condition being treated	NHSGGC Decision	Date of decision

anastrazole NCMAG113	primary prevention of breast cancer in post-menopausal people at moderate or high risk	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
axicabtagene ciloleucel Yescarta® SMC2695	Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
bictegravir, emtricitabine, tenofovir alafenamide Biktarvy® SMC2760	treatment of human immunodeficiency virus-1 (HIV-1) infection in paediatric patients at least 2 years of age and weighing at least 14 kg to less than 25 kg without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.	Not routinely available as not recommended for use in NHSScotland	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
cabotegravir Apretude® SMC2718	injection: in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg. tablets: in combination with safer sex practices for short term pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents, weighing at least 35 kg. Cabotegravir tablets may be used as: - oral lead-in to assess tolerability of cabotegravir prior to administration of long acting cabotegravir injection. - oral PrEP for individuals who will miss planned dosing with cabotegravir injection.	Routinely available in line with national guidance	17/02/2025
cemiplimab Libtayo® SMC2719	monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
ciclosporin Cequa® SMC2739	Treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears.	Routinely available in line with local or regional guidance	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
crovalimab Piasky® SMC2728	Monotherapy for the treatment of adult and paediatric patients 12 years of age or older with a weight of 40 kg and above with paroxysmal nocturnal haemoglobinuria (PNH): - In patients with haemolysis with clinical symptom(s) indicative of high disease activity. - In patients who are clinically stable after having been treated with a complement component 5 (C5) inhibitor for at least the past 6 months.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
danicopan Voydeya® SMC2675	Add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
dasatinib NCMAG116	Treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) integrated with chemotherapy	Routinely available in line with local or regional guidance	17/02/2025
dasatinib NCMAG117	Dasatinib for the treatment of adult patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy	Routinely available in line with local or regional guidance	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
durvalumab Imfinzi® SMC2734	In combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
elranatamab Elrexfio® SMC2669	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
etranacogene dezaparvovec Hemgenix® SMC2649	treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
fenfluramine Fintepla® SMC2723	Treatment of seizures associated with Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.	Routinely available in line with local or regional guidance	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
fosdenopterin Nulibry® SMC2624	Treatment of patients with molybdenum cofactor deficiency (MoCD) Type A	Routinely available in line with national guidance	17/02/2025
iptacopan Fabhalta® SMC2676	Monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
ivosidenib Tibsovo® SMC2664	Monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who were previously treated by at least one prior line of systemic therapy.	Routinely available in line with local or regional guidance	17/02/2025
lebrikizumab Ebglyss® SMC2707	Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
lecanemab Leqembi® SMC2700	Treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoEε4) heterozygotes or non-carriers.	Not routinely available as not recommended for use in NHSScotland	17/02/2025
linzagolix Yselty® SMC2631	Treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
mavacamten Camzyos® SMC2618	Treatment of symptomatic (New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
netarsudil, latanoprost Roclanda® SMC2720	Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction.	Routinely available in line with national guidance	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
olaparib Lynparza® SMC2737	Monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
pegunigalsidase alfa Elfabrio® SMC2665	for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
pembrolizumab Keytruda SMC 2689	As monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
pembrolizumab Keytruda® SMC2660	in combination with fluoropyrimidine and platinum-containing chemotherapy, for the first-line treatment of locally advanced unresectable or metastatic human epidermal growth factor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express programmed death-ligand 1 (PD-L1) with a combined positive score (CPS) ≥ 1.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
quizartinib Vanflyta® SMC2699	In combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
raloxifene NCMAG114	Primary prevention of breast cancer in post-menopausal people at moderate or high risk who are not suitable for on-label alternatives.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
relugolix, estradiol, norethisterone acetate Ryeqo® SMC2666	In adult women of reproductive age for symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.	Routinely available in line with local or regional guidance	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
risankizumab Skyrizi® SMC2686	treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy	Routinely available in line with local or regional guidance	17/02/2025
rozanolixizumab Rystiggo® SMC2761	Add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive	Not routinely available as not recommended for use in NHSScotland	17/02/2025
Selinexor Nexpovio SMC 2674	In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Routinely available in line with local or regional guidance	17/02/2025
Selinexor Nexpovio SMC 2673	In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.	Routinely available in line with local or regional guidance	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
Semaglutide Wegovy SMC2497	An adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of •≥30kg/m2 (obesity), or •≥27kg/m2 to <30kg/m2 (overweight) in the presence of at least one weight-related comorbidity.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
sirolimus Hyftor® SMC2710	Treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.	Routinely available in line with national guidance	17/02/2025
tamoxifen NCMAG115	Primary prevention of breast cancer in people at moderate or high risk	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
teclistamab Tecvayli® SMC2668	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
tirzepatide Mounjaro® SMC2653	For weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
trametinib NCMAG118	Treatment of low grade serous ovarian cancer after at least one line of platinum-based chemotherapy	Routinely available in line with local or regional guidance	17/02/2025
ublituximab Briumvi® SMC2731	Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Routinely available in line with local or regional guidance	17/02/2025
vamorolone Agamree® SMC2721	Treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.	Routinely available in line with national guidance	17/02/2025

Medicine	Condition being treated	NHSGGC Decision	Date of decision
vibegron Obgemsa® SMC2696	Symptomatic treatment of adult patients with overactive bladder (OAB) syndrome.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025
zanubrutinib Brukinsa® SMC2684	Monotherapy for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by: 28/04/2025	17/02/2025